Barinthus Biotherapeutics plc - ADR
News
Is Barinthus Biotherapeutics (NASDAQ:BRNS) In A Good Position To Invest In Growth?
Simply Wall St Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...\n more…
Barinthus Biotherapeutics plc (NASDAQ:BRNS) Expected to Earn Q3 2024 Earnings of ($0.49) Per Share
Zolmax Barinthus Biotherapeutics plc (NASDAQ:BRNS - Free Report) - Stock analysts at HC Wainwright dropped their Q3 2024 earnings estimates for shares of Barinthus Biotherapeutics in a research report...\n more…
Barinthus Biotherapeutics (NASDAQ:BRNS) PT Lowered to $9.50
Ticker Report Barinthus Biotherapeutics (NASDAQ:BRNS - Get Free Report) had its target price decreased by investment analysts at Alliance Global Partners from $11.00 to $9.50 in a note issued to investors on...\n more…
Barclays Remains a Buy on Barinthus Biotherapeutics (BRNS)
TipRanks Financial Blog Barclays analyst Carter Gould maintained a Buy rating on Barinthus Biotherapeutics (BRNS - Research Report) today and set a price target of $3.00. ...\n more…
Barinthus Biotherapeutics plc (NASDAQ:BRNS) Sees Large Decline in Short Interest
Ticker Report Barinthus Biotherapeutics plc (NASDAQ:BRNS - Get Free Report) saw a large decline in short interest during the month of July. As of July 31st, there was short interest totalling 14,800 shares, a...\n more…